A series of novel spiro-heteroazolones derived from a 2,3-dihydropyrano[2,3-b]pyridine ring system have been prepared, including their pharmaceutically acceptable salts. These compounds are useful in therapy as aldose reductase inhibitors for the control of certain chronic diabetic complications. Typical member compounds include spiro-imides, spiro-oxazolidinediones, spiro-thiazolidinediones and spiroimidazolidinediones derived from the aforesaid ring system. (4'S)(2'R)-6'-Chloro-2',3'-dihydro-2'-methyl-spiro-[imidazolidine-4,4'-4'H-py- rano[2,3-b]pyridine]-2,5-dione represents a typical and preferred member compound. Methods for preparing all these compounds from known starting materials are provided.
我们制备出了一系列新型螺杂环唑
酮类化合物,它们来自
2,3-二氢吡喃并[2,3-b]
吡啶环系统,包括其药学上可接受的盐类。这些化合物可作为醛糖还原酶
抑制剂用于治疗,以控制某些慢性糖尿病并发症。典型的成员化合物包括由上述环系统衍生的螺烷基
亚胺、螺烷基
噁唑烷二酮、螺烷基
噻唑烷二酮和螺烷基
咪唑烷二酮。(4'S)(2'R)-6'-
氯-2',3'-二氢-2'-甲基-螺-[
咪唑烷-4,4'-4'H-
吡喃并[2,3-b]
吡啶]-2,5-二酮代表了一种典型的优选成员化合物。本文提供了用已知起始原料制备所有这些化合物的方法。